ELIXOPHYLLIN SR Drug Patent Profile
✉ Email this page to a colleague
When do Elixophyllin Sr patents expire, and what generic alternatives are available?
Elixophyllin Sr is a drug marketed by Forest Labs and is included in one NDA.
The generic ingredient in ELIXOPHYLLIN SR is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Elixophyllin Sr
A generic version of ELIXOPHYLLIN SR was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ELIXOPHYLLIN SR?
- What are the global sales for ELIXOPHYLLIN SR?
- What is Average Wholesale Price for ELIXOPHYLLIN SR?
Summary for ELIXOPHYLLIN SR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 171 |
Clinical Trials: | 1 |
Patent Applications: | 3,995 |
DailyMed Link: | ELIXOPHYLLIN SR at DailyMed |
Recent Clinical Trials for ELIXOPHYLLIN SR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University Medical Center | Phase 2 |
US Patents and Regulatory Information for ELIXOPHYLLIN SR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Forest Labs | ELIXOPHYLLIN SR | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 086826-001 | Jan 29, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Forest Labs | ELIXOPHYLLIN SR | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 086826-002 | Jan 29, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |